Spirox's Latera nasal implant racks up positive results

Spirox is touting results from a study of its Latera absorbable nasal implant, a device designed to fight nasal valve collapse and obstruction.

Latera is an absorbable polymer implant that supports the nasal cartilage and is placed by a surgeon.

The study showed that, over the course of a year, patients showed significant improvement in their quality of life, including less nasal blockage or obstruction, less trouble breathing and better sleep. Symptoms were relieved by more than 50% in a year with the device.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Nasal valve collapse has historically been underdiagnosed, as the limited number of options that physicians have to support the lateral cartilage are generally invasive and have the potential to permanently alter appearance,” study author Marion San Nicoló said. “I am excited that we now have a minimally invasive technology that enables us to effectively and safely support patients’ lateral cartilage and help improve their breathing. Many of my patients felt immediate relief from the implant and no patients had negative cosmetic changes.”

In April last year, Spirox picked up $18.5 million to support development of the device, which is still up for U.S. marketing authorization.

Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.